Abstract
Introduction
Dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are synucleinopathies characterized by a progressive dementia syndrome and prominent psychiatric symptoms, usually associated with parkinsonism and typically dominated by attention, visuospatial and executive dysfunction, and relatively preserved memory [1, 2] . DLB accounts for 10-20% of people with late-onset dementia [2] , and PDD eventually develops in the majority of older patients with Parkinson disease (PD) [3] . Current treatment strategies are limited to symptomatic approaches with acetyl cholinesterase inhibitors (AChEIs), conferring significant but limited benefits in cognitive function and neuropsychiatric symptoms in both PDD and DLB [4, 5] . Depression is one of the main neuropsychiatric disorders associated with cognitive decline [6] , has been established as a risk factor for dementia [7, 8] , and is frequent and challenging in neurodegenerative diseases including PD [9] , DLB [1, 10] , and Alzheimer disease (AD) [11] .
Impaired neurogenesis is increasingly recognized as a key feature in aging and neurodegeneration. Age-related alterations in neurogenesis have been reported in post-mortem human brain [12, 13] and to a greater extent in a range of neurodegenerative conditions including AD, DLB, and PD [14] [15] [16] [17] [18] [19] . It has therefore been hypothesized that neurogenic dysfunction may contribute to cognitive impairment or may even represent a novel treatment target. Human autopsy studies have compared key markers of adult neurogenesis in the neurogenic niches in patients with synuclein disorders and age-matched controls. These studies report a significant decrease in early stage progenitor markers Musashi1 and Nestin, but a significant increase in the cell proliferation marker proliferating cell nuclear antigen and the later stage neuronal precursor marker DCX in people with DLB [16] [17] [18] . However, no study to date has examined the relationship between altered neurogenesis and the rate of cognitive decline and/or the impact of pharmacological treatments upon neurogenesis in DLB/PDD. These are both vital steps in determining the potential clinical significance of neurogenesis as a treatment target in these dementias.
A key potential factor in the relationship between neurogenesis, cognition, and treatment response is the link between depression and neurogenesis. This is particularly pertinent due to the commonality of depression in people with DLB and PDD [20, 21] . Post-mortem studies comparing hippocampal neurogenesis between people with depression and age-matched controls have reported conflicting results [22, 23] . There is consistent evidence showing a decrease in the volume of the hippocampal dentate gyrus (DG), the main adult neurogenic niche, in patients with depression or anxiety [24, 25] , including a meta-analysis comparing 32 MRI studies [26] as well as supporting data showing that hippocampal volume is less affected in patients treated with anti-depressants [27] . There is no evidence to show that hippocampal volume is lowered as a direct result of impaired neurogenesis alone, and other factors such as cell soma size, dendritic complexity, and glial cell size and number could contribute to this phenomenon in depression. Evidence also suggests that there is a lower number of neural progenitor cells and mitotic cells in the DG of older depressed patients compared to controls [22] . Taken together, these data therefore suggest a potential link between depression and reduced neurogenesis and/or reduced survival of neural progenitors.
Rodent studies have clearly demonstrated that selective serotonin reuptake inhibitor (SSRI) administration, the most frequently used class of antidepressant treatment, significantly increases neurogenesis [28] [29] [30] . Comparable findings have been observed in in vitro studies using human hippocampal progenitor cells [31] . Mechanisms that have been postulated as drivers of this effect include serotonergic mediation of neurogenesis, activation of the glucocorticoid receptor, and an impact of key trophic factors such as BDNF [31] [32] [33] [34] . It is therefore possible that SSRI administration may contribute to increased neurogenesis in people with depression or anxiety.
This study sought to elucidate the relationships between neurogenesis, cognition, and SSRI treatment response in DLB and PDD. A better understanding of this association could have considerable implications for the treatment of depression in these conditions. This work also represents a novel avenue in identifying drivers of disease progression and treatment targets in clinically defined groups within the overall dementia patient group.
Subjects, Diagnosis, and Assessments
Paraffin-embedded human autopsy hippocampal tissue at the level of the geniculate nucleus from PDD and DLB patients (n = 41) and age-matched controls (n = 15) was obtained from the Newcastle (UK) Brain Tissue Resource, with consent from next of kin, and University Hospital, Stavanger (Norway), with consent from patients, and in accordance with the approval of the Joint Ethics in Medical Research, University of Bergen, and the Medical Research Council (MRC). Neuropathological assessment and diagnosis followed the international consensus criteria for DLB [1] . Patients meeting the consensus pathological criteria for DLB, but with PD for more than 1 year prior to the onset of dementia were diagnosed as PDD. Brain tissue used in this study was selected to match confounding factors such as age and fixation time of tissue. Control cases were neurologically normal, with only mild age-associated neuropathological changes and no history of psychiatric disease. The neuropathological features in these subjects were not of sufficient severity to be considered associated with dementia (e.g., neurofibrillary tangle Braak stages below IV [35] ). Controls were also not medicated with SSRIs during life. No MMSE assessments were carried out on control subjects.
Depression was assessed in the DLB/PDD patients using serial scores from a standardized assessment instrument. The main assessments used were the Montgomery-Åsberg Depression Rating Scale (MADRS) where scores above 13 were indicative of, at least, mild depression [36] and Cornell Scale for Depression in Dementia (CSDD), where scores above 9 were indicative of probable depression [36] . The information from these serial evaluations was converted into a binary variable of depression over the course of the dementia or no depression.
Cognitive data were collected from MMSE examinations for DLB/PDD patients. Final MMSE scores, measured at least within 2 years prior to death, were available for 39 out of 41 DLB/PDD patients. The average rate of annual cognitive decline per patient was determined by the number of MMSE points lost over the number of years with dementia from the maximum MMSE score: [(30 -MMSE score closest to death)/ years with dementia] and was available for 35 out of the 41 DLB/PDD patients. Administration of SSRIs and AChEIs was assessed based on the medication notes of the last 3 consecutive years prior to death.
Immunohistochemistry
Paraffin-embedded coronal human hippocampal brain sections were sectioned at 7-µm thickness. Sections were de-paraffinized, rehydrated, and microwave-treated in citrate buffer, pH 6.0 for 6 min using a pressure cooker to expose epitopes. The endogenous peroxidase activity was quenched for 20 min in 3% H 2 O 2 in tris-buffered saline. Sections were immunostained for doublecortin (DCX; sc-8066, 1: 200; Santa Cruz Biotechnology, Dallas, TX, USA) for 48 h at 4 ° C. After subsequent washes, sections were incubated with the appropriate secondary HRP-conjugated antibody (PI-9500, 1: 250; Vector Laboratories, UK) for 2 h at room temperature. After washes, sections were developed with diaminobenzidine substrate (Vector Laboratories). Counterstaining was performed with haematoxylin. Adjacent sections were incubated in the absence of the primary or secondary antibodies in order to determine non-specific antibody binding, and were devoid of immunoreactivity (data not shown). All immunohistochemistry was performed blind to clinical and pathological diagnosis.
Cell Counting
Cell counting was performed using an E800 Eclipse, Nikon microscope (Nikon, UK), and the NIS Elements software version 3.0 (Nikon, UK). The extent of DG immunostaining per case depended exclusively on the amount of tissue supplied by the brain banks. Since, in most cases, this corresponded to a single section of DG, the length of DG within the section was measured using low magnification and software tools. Cells immunopositive for DCX were then counted throughout the entire DG and absolute number expressed per mm of length of DG. All cell measurements were carried out blind to clinical and pathological diagnosis.
Statistical Analysis
Statistical analyses were performed using SPSS version 22.0 software (IBM) and GraphPad Prism version 7.0 (GraphPad Software). Post-mortem delay (PMD) was found to be significantly correlated with DCX values in the SGZ by Spearman's rank correlation (Spearman's rho, ρ = 0.321, p = 0.016) and a significant predictor of DCX levels in the SGZ via regression analysis (R = 0.340, p = 0.010). PMD was therefore controlled for in statistical analyses, as described below. Two of the DLB/PDD cases had missing PMD values. These values were therefore imputed from the mean. No other demographic factors correlated with DCX immunoreactivity in the SGZ.
An independent samples Mann-Whitney U test was performed to determine alteration in DCX levels in the SGZ in DLB/PDD patients compared to controls. PMD did not differ significantly between dementia patients and controls (Mann-Whitney U, p = 0.410) and was therefore not included as a co-variate in this test. One-way analysis of covariance (ANCOVA) was conducted to compare endogenous hippocampal neurogenic immunoreactivity in the different treatment groups, including PMD as a covariate. Partial correlation analysis was performed to determine the association between the MMSE score closest to death and average rate of annual decline in MMSE score, and the number of DCX-immunopositive cells, controlling for PMD and duration of dementia in years.
An independent samples Student's t test was performed to compare mean number of DCX-positive cells in the depressed compared to non-depressed dementia patients. PMD did not differ significantly between depressed and non-depressed patients (Mann-Whitney U, p = 0.545) and was therefore not included as a co-variate in this test.
Data are presented as mean ± standard deviation of the mean (SD). Statistical significance was considered as p ≤ 0.05.
Results

Cohort Characteristics
The mean age at death across the whole cohort was 80.11 ± 6.24 years (80.47 ± 8.48 years in controls and 79.98 ± 5.32 years in DLB/PDD), and genders were equally represented (48% males, 52% females).
In the dementia patients, mean duration of dementia was 4.6 ± 2.9 years, and mean MMSE score closest to death was 11.9 ± 7.8 (for details see Table 1 ). Figure 1 illustrates DCX-positive cells within the hippocampal SGZ, as detected by diaminobenzidine immunohistochemistry. Consecutive sections from cases exhibiting no DCX-positive cells were subsequently stained for other markers to assess antigenicity of the tissue (data not shown). Fig. 2a) . A significantly higher DCX immunoreactivity was also observed in the SGZ of those DLB/PDD patients who were not treated with SSRIs or AChEIs (n = 13) compared to age matched controls (n = 15) (MannWhitney U test, W = 168.0, Z = -2.29, p = 0.022; Fig. 2a ), suggesting that this increase is independent of a treatment effect.
Correlation of Neurogenesis and Cognitive Decline in DLB/PDD
DCX levels in the SGZ at post-mortem were significantly correlated with higher MMSE scores closest to death (n = 39, r = 0.44, p = 0.006; Fig. 2b) , and a slower rate of cognitive decline (n = 35, r = -0.396, p = 0.023; Fig. 2c ). These results remained consistent in the SSRI treatment group (±AChEIs) with DCX levels being significantly correlated with both MMSE scores closest to death (n = 14, r = 0.615, p = 0.033) and a slower rate of cognitive decline (n = 14, r = -0.640, p = 0.025). Similar correlation analyses did not yield statistically significant results for the AChEI treatment group (±SSRIs) ( Table 2) . Table 2 further lists partial correlation analyses between DCX SGZ levels and MMSE scores for the individual treatment groups; however, since n numbers are relatively low in these subgroups, one must use caution in interpreting these data.
Association of SSRI Treatment and DCX Levels in DLB/PDD
In order to evaluate whether treatment with SSRIs or AChEIs was associated with altered hippocampal neurogenesis, the mean number of DCX-positive cells in the SGZ of the hippocampal DG across the different treatment groups was evaluated (Fig. 2d) . One-way ANCOVA analysis (independent variable: treatment type (controls, no treatment, AChEIs, SSRIs, AChEIs + SSRIs), covariate: PMD) indicated a significant treatment effect on the number of neural progenitors in the SGZ (F = 7.540, df = 4, 50, p ≤ 0.001). Post hoc analysis suggested that the strongest influence on DCX-positive cell number was the SSRI treatment (SSRI: n = 6 compared to controls: n = 15, p ≤ 0.001, and compared to untreated DLB/PDD: n = 13, p = 0.001). DCX levels were also significantly higher in patients undergoing SSRI treatment compared to patients treated with AChEIs only (n = 12, p = 0.002). The patients treated with both SSRIs and AChEIs (n = 10) did not exhibit a significant change in DCX immunoreactivity compared to the other DLB/PDD treatment groups but exhibited higher DCX levels in the SGZ than controls (p < 0.001).
As an additional sensitivity analysis within the dementia group, the one-way ANCOVA analysis was repeated with all patients receiving SSRIs (±AChEIs) combined into one group (n = 16). This group also showed greater DCX levels compared to the group receiving no SSRI treatment (one-way ANCOVA, independent variable: antidepressant treatment [no treatment, AChEIs, SSRIs ± AChEIs], covariate: PMD, F = 5.520, df = 2.37, p = 0.008). Post hoc analysis suggested that SSRI treatment (n = 16) is associated with greater DCX levels both when compared to no treatment (n = 13) (p = 0.023) and when compared to AChEIs-only treatment (n = 12) (p = 0.024).
Impact of SSRI Treatment in DLB/PDD in the Context of Clinical Depression
Standardized depression assessments were available for 35 out of 41 DLB/PDD patients, 16 of whom had presented a history of clinical depression during the course of the dementia. There was no difference in mean DCX levels in the SGZ of depressed (n = 16) and nondepressed dementia patients (n = 19) (independent samples Student's t test, t = -0.105, df = 33, p = 0.917). DCX immunoreactivity in the SGZ of DLB/PDD patients with depression was significantly different between patients receiving SSRI, AChEIs, or no treatment (one-way ANCOVA, independent variable: treatment type (no treatment, AChEIs, SSRIs, AChEIs + SSRIs), covariate: PMD, F = 4.918, df = 3, 11, p = 0.021) but no such treatment-related differences were observed in DLB/PDD patients without a history of depression (one way ANCOVA, F = 1.557, df = 3, 14, p = 0.244).
Discussion
The study has examined the inter-relationships between neurogenesis, cognition, and treatment of depression in people with DLB/PDD. The findings suggest an association between preserved cognition and increased neurogenesis in DLB/PDD patients, and highlight a significant increase in neurogenesis in patients treated with SSRIs. The impact of SSRIs on neurogenesis was largely seen in patients with concurrent depression. This study builds on previously published studies, particularly one report of a greater number of late-stage neural progenitors in the hippocampus in patients with DLB/PDD compared to age-matched controls [16] , which was further increased by treatment with SSRIs. The results highlight endogenous neurogenesis as an important and clinically relevant phenomenon in DLB/PDD patients, and suggest neurogenesis as a treatment target. Of particular note, the work also emphasizes that Since this is a partial correlation analysis controlling for two co-variates (years of dementia duration and post-mortem interval), the degrees of freedom (df) represent n -4. MMSE, Mini-Mental State Examination; AChEIs, acetylcholinesterase inhibitors; SSRIs, selective serotonin reuptake inhibitors.
proactive treatment of concurrent depression may be particularly important in these individuals.
Treatment with SSRIs has been shown to increase neurogenesis in vivo in animals [37] , including non-human primates [38] . The elevation in hippocampal neural progenitor cells may be a neural compensatory mechanism to the degenerative process, which can be further augmented by SSRI treatment. This raises the possibility that other more potent regulators of neurogenesis, such as erythropoietin, retinoids, and cannabinoids may be novel candidates for the treatment of DLB/PDD patients [39] [40] [41] [42] .
The cholinergic system has also been implicated in hippocampal neurogenesis, and postmortem studies have shown that cholinergic pathology may be involved in reducing neurogenesis in AD [14, 18] . Our results suggest that the number of DCX-positive cells in the hippocampus is greater following treatment with SSRIs than treatment with AChEIs in DLB/PDD patients.
The results of this study demonstrated that the higher SGZ DCX expression following antidepressant treatment was especially significant in the depressed group. Depression occurs in approximately 30% of DLB/PDD patients [43] , and there is currently a considerable gap in the evidence base relating to the treatment of depression in these individuals. SSRIs and other antidepressants are also commonly used to treat symptoms such as agitation and sleep disturbance in dementia. The results of the current study emphasize the importance of proactive treatment of depression in people with DLB/PDD, but also highlight the need for treatment trials clarifying the impact of antidepressant treatment on cognition, function, disease progression, and neurogenesis.
Although this is a large prospectively studied cohort for a post-mortem study, there are some limitations to power for statistical analysis of subgroup comparisons. Different institutions from which the tissue was obtained used different rating scales for measuring depression, restricting analysis to the use of a binary variable. It is also important to consider potential confounding factors which may have influenced the relationship between neurogenesis and cognitive decline when interpreting the data. Since duration of dementia impacts cognitive decline, the number of years with dementia was controlled for in the partial correlation analyses investigating the association between DCX immunoreactivity and MMSE score closest to death. In addition, there was also a significant relationship between higher DCX levels and the rate of cognitive decline. These findings therefore suggest that increased neurogenesis in the DG is associated with preserved cognition.
It is important to note that the main focus of this preliminary study was neurogenesis in the DG which is considered the main and the most extensively studied neurogenic niche in the adult mammalian brain. Recent evidence suggests that in the human brain, neuronal precursors originating in the additional mammalian neurogenic niche, the subventricular zone (located in the lateral ventricles), might be contributing to new neurons in the striatum [44] , a brain region greatly implicated in the parkinsonian syndrome associated with DLB and PDD. An investigation of the potential relationship between neurogenesis in the subventricular zone and DLB/PDD would, therefore, be of great interest.
The mechanisms by which newly generated neurons following SSRI treatment have an impact on cognition and general brain function are still a question of debate in the field. Studies suggest that newly generated granule cells in animals exhibit greater synaptic plasticity than older ones and are preferentially integrated into circuits where they might be acting as circuit modulators [45, 46] . Therefore, these albeit few neurons, newly generated in certain regions of the adult brain, might be playing an important role in both stabilizing and altering the plastic brain network -this role might be especially crucial in cases of severe pathological alterations, as in dementia.
Due to the fact that the findings outlined above arise from a post-mortem study and not a randomized controlled trial, we are cautious in interpreting our data and emphasize that future work is required to further validate these results. Samples of DG analyzed relied on the generosity of wax sections supplied by brain banks, most of which were no more than a few individual sections per case study. DCX immunopositivity was therefore normalized to length of the DG within each section. Future studies using more quantitative techniques such as stereology could better investigate expression of neurogenic markers in relation to total neuronal cell count and offer further insight into the clinical relevance of such findings. In this study, DLB and PDD cases were grouped together as one Lewy body dementia cohort to investigate effects of antidepressant treatment on neurogenesis and cognition. Whilst the 1-year rule is still routinely clinically applied to differentiate between the two dementia forms, several studies have suggested differences in amyloid load and Lewy body cortical load [47] [48] [49] [50] [51] which could also have an impact on the rate of neurogenesis. It would, therefore, be of interest to take this into consideration in future studies investigating neurogenesis in DLB/ PDD. Nevertheless, our study is the first illustrating that hippocampal neurogenesis may be a clinically relevant phenomenon in DLB/PDD patients, correlating with the progression of cognitive impairment and enhanced by pharmacological treatment with SSRIs.
Overall, although preliminary, this study suggests the serotonergic system may be a novel therapeutic target to maintain cognitive and neurogenic function in DLB and PDD patients. The results also emphasize the importance of proactive and effective treatment of depression in people with DLB/PDD.
